Entera Bio Ltd (ENTX): Price and Financial Metrics
ENTX Price/Volume Stats
| Current price | $2.24 | 52-week high | $3.35 |
| Prev. close | $2.22 | 52-week low | $0.52 |
| Day low | $2.18 | Volume | 167,400 |
| Day high | $2.32 | Avg. volume | 211,552 |
| 50-day MA | $1.54 | Dividend yield | N/A |
| 200-day MA | $0.93 | Market Cap | 64.52M |
ENTX Stock Price Chart Interactive Chart >
Entera Bio Ltd (ENTX) Company Bio
Entera Bio Ltd operates as a biotechnology company. The Company specializes in the oral delivery of molecules and biologics. Entera Bio also develops candidates for the treatment of osteoporosis. Entera Bio serves patients in the United States and Israel.
Latest ENTX News From Around the Web
Below are the latest news stories about ENTERA BIO LTD that investors may wish to consider to help them evaluate ENTX as an investment opportunity.
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors. The Company issued and sold 7,916,879 units at a price of $0.835 per unit, each consisting of one ordinary share of Entera (or one pre-funded warrant in lieu thereof), and one five-year warrant. Gross pr |
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformJERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to assess and compare the pharmacokinetic (PK) and early pharmacodynamic (PD) profile of current and several next generation compositions of its oral peptide platform (NCT05965167). EB613 Continues to Display an Optimal Profile as First-in-Class |
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentJERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023. “Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company. It is our goal to potentially move five high value, first-in-class programs, Phase |
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisJERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral |
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual MeetingJERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com. “Entera’s ability to consistently deliver our oral PTH(1-34) peptide in a simple mi |
ENTX Price Returns
| 1-mo | 47.37% |
| 3-mo | 124.02% |
| 6-mo | 235.03% |
| 1-year | 163.56% |
| 3-year | -23.55% |
| 5-year | -46.67% |
| YTD | 273.33% |
| 2023 | -17.81% |
| 2022 | -74.07% |
| 2021 | 160.65% |
| 2020 | -49.53% |
| 2019 | -29.84% |
Loading social stream, please wait...